Skip to main content

Table 2 Cost per one averted hospitalisation, compared to no intervention

From: Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada

 

South

NWT

Nunavut

Nunavik

NIRS HR

Cost saving

Cost saving

Cost saving

Cost saving

NIRS HR + MR

$8139

Cost saving

Cost saving

Cost saving

ABR SEASONAL

$23,896

Cost saving

Cost saving

Cost saving

ABR SEASONAL + NIRS

$23,790

Cost saving

Cost saving

Cost saving

ABR ALL

$36,396

$6511

Cost saving

Cost saving

ABR ALL + NIRS

$36,378

$6247

Cost saving

Cost saving

NIRS < 6

$49,683

$14,486

Cost saving

Cost saving

NIRS ALL

$53,113

$16,441

Cost saving

Cost saving

  1. ABR RSVpreF, HR high risk, MR medium risk, NIRS nirsevimab, PVZ palivizumab